Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Jorg Oddens*, Maurizio Brausi, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Wolfgang Hoeltl, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)462-472
JournalEuropean Urology
Issue number3
Publication statusPublished - Mar 2013


  • Non-muscle invasive bladder cancer
  • Randomized Controlled Trial
  • Immunotherapy
  • Bacillus Calmette-Guerin
  • Adjuvant treatment
  • Urinary bladder
  • Maintenance therapy

Cite this